Shield Therapeutics plc (SHIEF)

Market Cap	113.59M +266.7%
Revenue (ttm)	41.50M +93.2%
Net Income	-21.24M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,169
Average Volume	6,940
Open	0.1083
Previous Close	n/a
Day's Range	0.1073 - 0.1083
52-Week Range	0.0331 - 0.1512
Beta	1.91
RSI	48.16
Earnings Date	Apr 24, 2026

About Shield Therapeutics

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 63
• Stock Exchange: OTCMKTS
• Ticker Symbol: SHIEF

Financial Performance

In 2024, Shield Therapeutics's revenue was $32.18 million, an increase of 145.93% compared to the previous year's $13.09 million. Losses were -$27.18 million, -18.36% less than in 2023.